We narrowed to 82,847 results for: Ina

1. pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (AAV8)

   Viral Prep

   #137120-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (#137120). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Cre recombinase (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth, INTRSECT 2.0 Project

   Article

   Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

   Promoter

   EF1a

   Tags

   None

   Available since

   Nov. 23, 2020

   Availability

   Academic Institutions and Nonprofits only

2. pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (AAV8)

   Viral Prep

   #137120-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (#137120). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Cre recombinase (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth, INTRSECT 2.0 Project

   Article

   Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

   Promoter

   EF1a

   Tags

   None

   Available since

   Nov. 23, 2020

   Availability

   Academic Institutions and Nonprofits only

3. pAAV CD68-hM4D(Gi)-mCherry (AAV1)

   Viral Prep

   #75033-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Bryan Roth

   Article

   Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

   Promoter

   CD68

   Tags

   mCherry

   Available since

   March 27, 2019

   Availability

   Academic Institutions and Nonprofits only

4. pAAV CD68-hM4D(Gi)-mCherry (AAV1)

   Viral Prep

   #75033-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Bryan Roth

   Article

   Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

   Promoter

   CD68

   Tags

   mCherry

   Available since

   March 27, 2019

   Availability

   Academic Institutions and Nonprofits only

5. pAAV CD68-hM4D(Gi)-mCherry (AAV9)

   Viral Prep

   #75033-AAV9

   Purpose

   Ready-to-use AAV9 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Bryan Roth

   Article

   Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

   Promoter

   CD68

   Tags

   mCherry

   Available since

   Sept. 27, 2023

   Availability

   Academic Institutions and Nonprofits only

6. pAAV CD68-hM4D(Gi)-mCherry (AAV9)

   Viral Prep

   #75033-AAV9

   Purpose

   Ready-to-use AAV9 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Bryan Roth

   Article

   Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

   Promoter

   CD68

   Tags

   mCherry

   Available since

   Sept. 27, 2023

   Availability

   Academic Institutions and Nonprofits only

7. AAV phSyn1(S)-DreO-bGHpA (AAV Retrograde)

   Viral Prep

   #50363-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from AAV phSyn1(S)-DreO-bGHpA (#50363). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-DreO-bGHpA plasmid DNA. hSyn-driven Dre recombinase expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Hongkui Zeng

   Article

   Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

   Promoter

   Syn

   Tags

   None

   Available since

   Aug. 18, 2020

   Availability

   Academic Institutions and Nonprofits only

8. AAV phSyn1(S)-DreO-bGHpA (AAV Retrograde)

   Viral Prep

   #50363-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from AAV phSyn1(S)-DreO-bGHpA (#50363). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-DreO-bGHpA plasmid DNA. hSyn-driven Dre recombinase expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Hongkui Zeng

   Article

   Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

   Promoter

   Syn

   Tags

   None

   Available since

   Aug. 18, 2020

   Availability

   Academic Institutions and Nonprofits only

9. pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (AAV5)

   Viral Prep

   #125712-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

   Promoter

   short version of αCamKinase II promoter (0.4kb)

   Tags

   mScarlet

   Available since

   June 26, 2024

   Availability

   Academic Institutions and Nonprofits only

10. pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (AAV5)

    Viral Prep

    #125712-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

    Promoter

    short version of αCamKinase II promoter (0.4kb)

    Tags

    mScarlet

    Available since

    June 26, 2024

    Availability

    Academic Institutions and Nonprofits only

11. pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (AAV1)

    Viral Prep

    #125712-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

    Promoter

    short version of αCamKinase II promoter (0.4kb)

    Tags

    mScarlet

    Available since

    June 26, 2024

    Availability

    Academic Institutions and Nonprofits only

12. pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (AAV1)

    Viral Prep

    #125712-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

    Promoter

    short version of αCamKinase II promoter (0.4kb)

    Tags

    mScarlet

    Available since

    June 26, 2024

    Availability

    Academic Institutions and Nonprofits only

13. AAV phSyn1(S)-FlpO-bGHpA (AAV Retrograde)

    Viral Prep

    #51669-AAVrg

    Purpose

    Ready-to-use AAV Retrograde particles produced from AAV phSyn1(S)-FlpO-bGHpA (#51669). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-FlpO-bGHpA plasmid DNA. hSyn-driven FlpO expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Hongkui Zeng

    Article

    Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

    Promoter

    Syn

    Tags

    None

    Available since

    Oct. 28, 2021

    Availability

    Academic Institutions and Nonprofits only

14. AAV phSyn1(S)-FlpO-bGHpA (AAV Retrograde)

    Viral Prep

    #51669-AAVrg

    Purpose

    Ready-to-use AAV Retrograde particles produced from AAV phSyn1(S)-FlpO-bGHpA (#51669). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-FlpO-bGHpA plasmid DNA. hSyn-driven FlpO expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Hongkui Zeng

    Article

    Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

    Promoter

    Syn

    Tags

    None

    Available since

    Oct. 28, 2021

    Availability

    Academic Institutions and Nonprofits only

15. pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (AAV5)

    Viral Prep

    #84446-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

    Promoter

    CAG

    Tags

    None

    Available since

    June 26, 2024

    Availability

    Academic Institutions and Nonprofits only

16. pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (AAV5)

    Viral Prep

    #84446-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

    Promoter

    CAG

    Tags

    None

    Available since

    June 26, 2024

    Availability

    Academic Institutions and Nonprofits only

17. pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (AAV1)

    Viral Prep

    #84446-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

    Promoter

    CAG

    Tags

    tdTomato

    Available since

    March 18, 2024

    Availability

    Academic Institutions and Nonprofits only

18. pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (AAV1)

    Viral Prep

    #84446-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

    Promoter

    CAG

    Tags

    tdTomato

    Available since

    March 18, 2024

    Availability

    Academic Institutions and Nonprofits only

19. pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (AAV5)

    Viral Prep

    #84445-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (#84445). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] plasmid DNA. CAG-driven, Cre-dependent Jaws-GFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

    Promoter

    CAG

    Tags

    GFP (Cre-dependent)

    Available since

    Oct. 10, 2018

    Availability

    Academic Institutions and Nonprofits only

20. pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (AAV5)

    Viral Prep

    #84445-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (#84445). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] plasmid DNA. CAG-driven, Cre-dependent Jaws-GFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Edward Boyden

    Article

    Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

    Promoter

    CAG

    Tags

    GFP (Cre-dependent)

    Available since

    Oct. 10, 2018

    Availability

    Academic Institutions and Nonprofits only